LANDOS BIOPHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.93 USD | +0.58% |
|
-.--% | +526.50% |
| May. 24 | Landos Biopharma, Inc.(NasdaqCM:LABP) dropped from S&P TMI Index | CI |
| May. 23 | AbbVie Completes Acquisition of Landos Biopharma | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 193.1 | 20.13 | 11.41 | 71.68 | - |
| Enterprise Value (EV) 1 | 193.1 | 20.13 | 11.41 | 71.68 | 71.68 |
| P/E ratio | -4.71 x | -0.51 x | -1.05 x | -9.76 x | -11.1 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | 10.7 x | - | - | - | - |
| EV / Revenue | 10.7 x | - | - | - | - |
| EV / EBITDA | -5,000,806 x | - | - | - | - |
| EV / FCF | -7,022,694 x | -439,763 x | - | - | - |
| FCF Yield | -0% | -0% | - | - | - |
| Price to Book | 2.53 x | - | - | - | - |
| Nbr of stocks (in thousands) | 4,024 | 4,025 | 3,117 | 3,126 | - |
| Reference price 2 | 48.00 | 5.001 | 3.660 | 22.93 | 22.93 |
| Announcement Date | 3/24/22 | 3/23/23 | 3/21/24 | - | - |
1USD in Million2
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 18 | - | - | - | - |
| EBITDA | - | -30.54 | -38.62 | - | - | - | - |
| EBIT 1 | -13.29 | -30.68 | -38.82 | -40.56 | - | -26.4 | -45 |
| Operating Margin | - | - | -215.64% | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -30.14 | -38.42 | -39.28 | - | -26.4 | -45 |
| Net income 1 | - | -30.14 | -38.42 | -39.28 | -21.94 | -26.4 | -45 |
| Net margin | - | - | -213.46% | - | - | - | - |
| EPS 2 | -21.60 | -24.70 | -10.20 | -9.800 | -3.500 | -2.350 | -2.070 |
| Free Cash Flow | - | -23.14 | -27.5 | -45.78 | - | - | - |
| FCF margin | - | - | -152.78% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 7/24/20 | 3/31/21 | 3/24/22 | 3/23/23 | 3/21/24 | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | 28.1 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | -23.1 | -27.5 | -45.8 | - | - | - |
| ROE (net income / shareholders' equity) | - | -345% | - | - | - | - |
| ROA (Net income/ Total Assets) | -74.6% | -62.4% | - | - | - | - |
| Assets 1 | 40.41 | 61.61 | - | - | - | - |
| Book Value Per Share | -42.30 | 18.90 | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex | 0.18 | 0.44 | - | - | - | - |
| Capex / Sales | - | 2.44% | - | - | - | - |
| Announcement Date | 3/31/21 | 3/24/22 | 3/23/23 | 3/21/24 | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +526.50% | 71.68M | |
| +43.36% | 54.64B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +0.04% | 12.16B | |
| +25.12% | 12.21B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- LABP Stock
- Financials Landos Biopharma, Inc.
